CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
LEE011 +1 moredrug
Likely dose
LEE011 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03070301
NCT03070301Phase 2Completed
CompareCT.gov

A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin

Memorial Sloan Kettering Cancer Center·interventional·Posted Mar 3, 2017·Updated Oct 10, 2024

In Brief

A Phase 2 clinical trial evaluating LEE011 and everolimus for Neuroendocrine Tumors. Completed, enrolled 21 participants across 5 sites.

Detailed Summary

The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
CollaboratorsNovartis, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 3, 2017
Enrollment StartFeb 27, 2017
Primary CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 9.3 years ago

Interventions

LEE011drug

LEE011 200 mg daily

everolimusdrug

everolimus 5 mg daily or 2.5mg daily